Obermatt
See Similar Stocks →

Sarepta Therapeutics

NSQ:SRPT · US8036071004
BiotechnologyLarge

360

69
EV / EBIT61
Price / Owner Earnings3
Owner Earnings Yield90
Dividend Yield1
Price/Sales84
EV / Gross Profit91
Price/Book66
Return on Capital80
Cash Return on Capital89
Return on Equity89
EBIT Margin59
Gross Profitability58
Accruals57
Owner Earnings Margin86
Sales growth16
Profit growth91
Reinvestment14
Price momentum9
Debt load42
Refinancing96
Debt Payback17
Liquidity57
Analyst ratings13
Opinion Changes24
Price Target Upside36
Market mood85
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Sarepta Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeLarge
TypePublic Company
ExchangeNASDAQGS
Founded1980
Employees1,027
Websitesarepta.com
ISINUS8036071004
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Stem Cell TherapyGeneticsCentral Nervous SystemGenetic DisorderBiotechnologyHealth CareScience and Engineering

Description

Sarepta Therapeutics, Inc. operates as a commercial-stage biopharmaceutical company. The company focuses on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy, and othe…

Analysis

Quality compounder

Sarepta Therapeutics, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is expensive. You pay 31.7× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is moderate and the balance sheet is stretched. The company scores 8/20 on our value-creation score: creating some value.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
82
2026

All-time high

82

Jun 2026

All-time low

57

Mar 2026

Average rank

70

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
84
—
—
—
Price/Earnings
41
—
—
—
Price/Book
66
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
79
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sarepta Therapeutics with its peers
PTC Therapeutics
NSQ:PTCT
12
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Krystal Biotech
NSQ:KRYS
96
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Xeris Pharmaceuticals
NSQ:XERS
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Tarsus Pharmaceuticals
NSQ:TARS
29
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Moderna
NSQ:MRNA
20
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →